<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348216</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-101</org_study_id>
    <nct_id>NCT02348216</nct_id>
  </id_info>
  <brief_title>A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)</brief_title>
  <acronym>ZUMA-1</acronym>
  <official_title>A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and
      efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell
      therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)</measure>
    <time_frame>30 Days</time_frame>
    <description>Incidence of adverse events defined as dose-limiting toxicities (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall Response Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Objective response rate (complete response [CR] + partial response [PR]) per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 Months</time_frame>
    <description>Incidence of adverse events and clinically significant changes in safety lab values, including subgroup analyses</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Refractory Diffuse Large B Cell Lymphoma</condition>
  <condition>Refractory Primary Mediastinal B Cell Lymphoma</condition>
  <condition>Refractory Transformed Follicular Lymphoma</condition>
  <condition>Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KTE-C19</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          1. Histologically confirmed:

               -  Diffuse Large B Cell Lymphoma (DLBCL)

               -  Primary Mediastinal Large B Cell Lymphoma (PMBCL)

               -  Transformation Follicular Lymphoma (TFL)

          2. Chemotherapy-refractory disease, defined as one of more of the following:

               -  No response to last line of therapy i. PD as best response to most recent
                  therapy regimen ii. SD as best response to most recent therapy with duration no
                  longer than 6 month from last dose of therapy OR

               -  Refractory post-ASCT i. Disease progression or relapsed less than or equal to 12
                  months of ASCT (must have biopsy proven recurrence in relapsed subjects) ii. If
                  salvage therapy is given post-ASCT, the subject must have had no response to or
                  relapsed after the last line of therapy

          3. Subjects must have received adequate prior therapy including at a minimum:

               -  anti-CD20 monoclonal antibody unless investigator determines that tumor is
                  CD20-negative and

               -  an anthracycline containing chemotherapy regimen

               -  for subjects with transformed FL must have received prior chemotherapy for
                  follicular lymphoma and subsequently have chemorefractory disease after
                  transformation to DLBCL

          4. At least one measurable lesion per revised IWG Response Criteria

          5. Age 18 or older

          6. Eastern cooperative oncology group (ECOG) performance status of 0 or 1

          7. ANC ≥ 1000/uL

          8. ALC &gt;100/uL

          9. Platelet count ≥ 75,000/uL

         10. Adequate renal, hepatic, pulmonary and cardiac function defined as:

               -  Creatinine clearance (as estimated by Cockcroft Gault) &gt; 60 mL/min

               -  Serum ALT/AST &lt;2.5 ULN

               -  Total bilirubin &lt;1.5 mg/dl, except in subjects with Gilbert's syndrome

               -  Cardiac ejection fraction &gt;50%, no evidence of pericardial effusion as
                  determined by an ECHO, and no clinically significant pleural effusion

               -  Baseline oxygen saturation &gt;92% on room air

         11. All subjects or legally appointed representatives/caregivers, must personally sign
             and date the IRB/IEC approved consent form before initiating any study specific
             procedures or activities.

        Key Exclusion Criteria

          1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g.
             cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3
             years

          2. History of allogeneic stem cell transplantation

          3. Prior CAR therapy or other genetically modified T cell therapy

          4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial
             pharyngitis are permitted if responding to active treatment

          5. Known history of infection with HIV or hepatitis B (HBsAG positive) or hepatitis C
             virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if
             the viral load is undetectable per quantitative PCR and/or nucleic acid testing

          6. Subjects with detectable cerebrospinal fluid malignant cells, or brain metastases, or
             with a history of CNS lymphoma, cerebrospinal fluid malignant cells or brain
             metastases

          7. History or presence of CNS disorder such as seizure disorder, cerebrovascular
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS
             involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Go, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kite Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Bowen, MPM, PMP, BS, BA</last_name>
    <phone>(404) 7927824</phone>
    <email>allison.bowen@theoremclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Horstman</last_name>
      <email>andrea.horstman@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarmad Bahrani</last_name>
      <email>sbahrani@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisma Montalvo</last_name>
      <email>kcmontalvo@ad.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Quintanilla</last_name>
      <email>dquintanilla@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Le</last_name>
      <email>ryanle@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juli Murphy</last_name>
      <email>juli.murphy@healthonecares.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nohelia Gonzalez</last_name>
      <email>NGonzalez5@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Edelman</last_name>
      <email>jeffrey.edelman@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Scott</last_name>
      <email>matthew.scott@moffitt.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Fahey</last_name>
      <email>kfahey@luc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at the University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Butcher</last_name>
      <email>susan-butcher@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Zehr</last_name>
      <email>pamela-zehr@uiowa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guadalupe DeMaeyer</last_name>
      <email>gdemaeyer@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Ventimiglia</last_name>
      <email>mellertk@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Jensen</last_name>
      <email>jensen.jennifer@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arrika Rayburn</last_name>
      <email>arayburn@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Blumel, RN, BSN, OCN</last_name>
      <email>sblumel@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren-Nicole Pascual</last_name>
      <email>lpascual@hackensackumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Joshua Zenreich</last_name>
      <email>jzenreich@hackensackumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Almanzar, MPH, CCRP</last_name>
      <email>lalmanza@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Baloga</last_name>
      <email>elizabeth_baloga@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Alberti</last_name>
      <email>sara_alberti@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Abounader</last_name>
      <email>abounad2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Cardona</last_name>
      <email>tiffany.cardona@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Harrison</last_name>
      <email>jill.harrison.whitaker@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Adkins</last_name>
      <email>sadkins@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Liliana Vallejo</last_name>
      <email>lnvallejo@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoDell McCracken</last_name>
      <email>jodell.mccracken@mhshealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avishag Sabag</last_name>
      <email>avishags@tlvmc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 3, 2016</lastchanged_date>
  <firstreceived_date>January 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
